Phase 1 Clinical Trial of Innate Immunity Stimulation via TLR9 in Early AD (Part the Cloud)

Brief description of study

The purpose of this study is to evaluate the safety, tolerability, and effectiveness of study drug called CpG 1018 ISS to slow or prevent Alzheimer’s disease (AD) progression. Alzheimer’s disease is caused by a buildup of amyloid and tau proteins in the brain. CpG 1018 ISS may trigger an immune response to reduce amyloid protein from building up in the brain. This study has three dose levels and is for patients who have been diagnosed with either mild cognitive impairment (MCI) or mild Alzheimer’s disease dementia. CpG 1018 ISS is considered investigational because it is not Food and Drug Administration (FDA) approved for preventing AD progression.

Clinical Study Identifier: s20-00267 Identifier: NCT05606341
Principal Investigator: Arjun V. Masurkar.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.